Healthtech Aisthesis Medical raises £892k led by Twin Path Ventures with TECS Capital
At a glance
This article covers a pre-seed funding round on 1 October 2025 for Aisthesis Medical, a UK-based healthtech startup developing hospital-grade AI clinical decision-support software, founded by Ioannis Gkouzionis, Vasilis Dimakopoulos and Sotiris Liliopoulos. The round raised £892k, led by TwinPath Ventures with participation from TECS Capital.
What does Aisthesis Medical do?
VIOSync SPI is a hospital software that uses AI to analyse patient vital signs and lab results. It predicts sepsis risk within 48 hours and presents explainable risk drivers to help clinicians prioritise care.
Why is Aisthesis Medical useful?
Problem
Frontline clinicians often cannot identify in-hospital sepsis before patient deterioration occurs. This delay prevents timely intervention and increases the risk of severe outcomes and death.
Solution
Aisthesis Medical explains that it securely ingests multimodal hospital data and builds a digital twin of patient physiology. The platform uses explainable AI to predict sepsis risk within 48 hours, giving clinicians transparent drivers and actionable insights.
How much did Aisthesis Medical raise?
Aisthesis Medical raised £892k ($1.2m) in a pre-seed round led by TwinPath Ventures, with participation from TECS Capital. This makes it the 1st largest funding round in October 2025 (1 recorded). It ranks 393rd of the year (470 recorded) in the Startupmag database, as of 1 October 2025.
For details on how Startupmag compiles its rankings, view our Methodology.
Who invested in Aisthesis Medical?
Key investors in the round included the following.
- Twin Path Ventures: A UK venture capital firm that invests in early-stage healthtech and deep-tech companies.
- TECS Capital: A venture capital firm focused on deep-tech and impact-driven healthcare and technology investments, active across the UK and EU.
In the funding announcement, Katie Lockwood from Twin Path Ventures said:
Sepsis is a silent killer that has long lacked predictive tools clinicians can trust. Aisthesis Medical’s combination of explainable AI, multimodal data integration, and digital twin technology is uniquely positioned to set a new standard in sepsis care.
The investor said they would back the team as it takes steps towards regulatory approval and market launch.
In the funding announcement, Antonis Ilias from TECS Capital said:
Backing Aisthesis Medical as our first investment in TECS Capital II reflects exactly the kind of impact-driven, deep-tech entrepreneurship we stand for. Transforming sepsis prediction with explainable AI goes beyond innovation, representing a life-saving shift in clinical practice.
The investor said they support the founding team in bringing the product to market as clinical validation proceeds in the UK and EU and the company follows a path toward CE MDR approval.
If you're researching potential backers in this space:
- Explore our list of healthtech venture capital firms in the UK
- Browse our directory of healthtech angel investors in the UK
Who founded Aisthesis Medical?
The founders of Aisthesis Medical are Ioannis Gkouzionis, Vasilis Dimakopoulos and Sotiris Liliopoulos.
In the funding announcement, Ioannis Gkouzionis, Co-founder & CEO of Aisthesis Medical said:
I’ve lived through sepsis twice. I know how quickly stability becomes a crisis and how much an earlier insight can change the outcome.
The company continued the platform is designed to give clinicians an explainable way to predict risk before symptoms emerge to enable earlier decisions, and the funding will help accelerate regulatory approvals and clinical adoption.
Where is Aisthesis Medical based?
Aisthesis Medical is based in London, UK.
What sector is Aisthesis Medical in?
Aisthesis Medical operates in the healthtech sector. The sector uses technology to improve healthcare services, diagnosis and patient outcomes. It helps doctors and nurses spot and treat illness earlier using digital tools.
Key trends and challenges in Healthtech:
AI for early detection
Hospitals increasingly use AI to flag deterioration, for example predicting sepsis risk within 48 hours.
Data integration and interoperability
Combining EHRs, monitors and lab systems remains hard, reducing tool accuracy and clinical usefulness.
Regulation and clinical validation
Tools need robust clinical trials and approvals, such as CE marking or MHRA review, before wide use.
For a deeper look at innovation in this space, see the healthtech startups in the UK.
They've invested in Aisthesis Medical
Get to know these healthtech investors
Click here for a full list of 7,233+ startup investors in the UK